Adicet Bio Inc. - Utang jangka cendhak perusahaan ACET

Adicet Bio is developing innovative T-cell therapies to combat lymphoma. Changes in short-term liabilities confirm current financial dynamics, where 0.00 reflects the latest metric value. Strategic collaboration with scientific centers is expanding the trial base, while partnership payments for joint projects support operational activities until the final stages of proprietary drug development are launched.

Adicet Bio (ACET) maintains complex cryogenic logistics to deliver viable cell therapies to cancer patients, which requires significant operating expenses. By analyzing the short-term borrowing ratio, an investor assesses obligations maturing within one year to determine the balance between financial flexibility and default risk, allowing this chart to reveal the business's ability to withstand macroeconomic shocks.